Overview

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and paclitaxel together with bevacizumab may kill more tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Bevacizumab
Carboplatin
Immunoglobulins
Paclitaxel